A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition:   Pulmonary Disease, Chronic ObstructiveInterventions:   Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg;   Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg;   Drug: Umeclidinium 62.5 mcg;   Device: Placebo ELLIPTA inahler;   Drug: Albuterol/SalbutamolSponsor:   GlaxoSmithKlineNot yet recruiting - verified April 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2016 Category: Research Source Type: clinical trials

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition:   Pulmonary Disease, Chronic ObstructiveInterventions:   Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg;   Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg;   Drug: Umeclidinium 62.5 mcg;   Device: Placebo ELLIPTA inhaler;   Drug: Albuterol/SalbutamolSponsor:   GlaxoSmithKlineNot yet recruiting - verified April 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2016 Category: Research Source Type: clinical trials

Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition:   Pulmonary Disease, Chronic ObstructiveInterventions:   Drug: FF/UMEC/VI;   Drug: FF/VI;   Drug: UMEC;   Drug: Placebo;   Drug: Albuterol/salbutamolSponsor:   GlaxoSmithKlineNot yet recruiting - verified March 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2016 Category: Research Source Type: clinical trials

Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)
Condition:   AsthmaInterventions:   Drug: MK-1029 150 mg;   Drug: Placebo for MK-1029;   Drug: Montelukast 10 mg;   Drug: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalationSponsor:   Merck Sharp & Dohme Corp.Not yet recruiting - verified March 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2016 Category: Research Source Type: clinical trials

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
Condition:   AsthmaInterventions:   Drug: Mepolizumab 100mg SC;   Drug: Albuterol/salbutamol MDIs;   Drug: OmalizumabSponsor:   GlaxoSmithKlineNot yet recruiting - verified January 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2016 Category: Research Source Type: clinical trials